4228-10-8

Usage

Uses

Used in Recreational Applications:
5-Acetylindane is used as a psychoactive stimulant for its stimulating, euphoric, and entactogenic effects. It is sought after by users for recreational purposes due to its ability to produce mood enhancement, increased energy, and heightened focus.
Used in Cognitive Enhancement Applications:
5-Acetylindane is used as a cognitive enhancer for its ability to increase levels of dopamine and norepinephrine in the brain, leading to improved mood, energy, and focus. Users seeking to enhance their cognitive performance may turn to 5-Acetylindane for its potential benefits.
Note: It is important to emphasize that 5-Acetylindane is not approved for human consumption and is illegal in many jurisdictions due to its potential for abuse and harmful health effects with excessive use. The uses mentioned above are based on the provided materials and do not endorse or promote the use of this substance.

InChI:InChI=1/C11H12O/c1-8(12)10-6-5-9-3-2-4-11(9)7-10/h5-7H,2-4H2,1H3

Upstream product

• 496-11-7 INDANE 
• 108-24-7 acetic anhydride 
• 75-36-5 acetyl chloride 
• 75-07-0 acetaldehyde 
• 75-15-0 carbon disulfide 
• 7446-70-0 aluminium trichloride 
• 69849-04-3 2-(1-ethoxyethoxy)-2-lithiopropanenitrile 
• 225642-90-0 1-(2,3,5,6-tetrahydro-1H-5-indenyl)1-ethanone 
• 64-19-7 acetic acid 

Downstream Products

• 65898-38-6 indan-5-carboxylic acid 
• 102445-12-5 6-indan-5-yl-3,4,6-trimethyl-cyclohex-3-enecarboxylic acid ethyl ester 
• 103204-17-7 indan-5-carboxamide 
• 101877-19-4 2-anilino-1-indan-5-yl-ethanone 
• 68634-03-7 3-oxo-indan-5-carboxylic acid methyl ester 
• 68634-02-6 methyl 2,3-dihydro-1-oxo-1H-indene-5-carboxylate 
• 86031-43-8 methyl 5-indanecarboxylate 
• 304648-59-7 2-hydroxymethyl-4-(5-indan-5-yl-3-trifluoromethyl-pyrazol-1-yl)-benzenesulfonamide 
• 19337-17-8 3--3-oxo-1-<4-chlor-phenyl>-propen-1 
• 23935-17-3 3-Dimethylamino-1-indan-5-yl-propan-1-one; hydrochloride 
• 16619-17-3 (E)-1-(2,3-dihydro-1H-inden-5-yl)-3-phenylprop-2-en-1-one 
• 4228-12-0 α-methyl-5-indane methanol 
• 52689-24-4 5-Ethylindan 
• 75078-87-4 <1-(5-indanyl)ethyl>-triphenylphophonium bromide 

Relevant academic research and scientific papers

Novel cyclic phospholipids used for treating HCV infection

The invention relates to novel cyclic phospholipids, pharmaceutically acceptable salts or esters thereof and a medicine composition used for treating HCV infection. Chlorine in a phenyl ring of a Hepdirect cyclic phospholipid prodrug is replaced by a spec

As a new polyphenylenepolymethylenepolyisocyanate deriv. SGLT2 inhibitor

A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.

Exploring naphthyl-carbohydrazides as inhibitors of influenza A viruses

A library of hydrazide derivatives was synthesized to target non-structural protein 1 of influenza A virus (NS1) as a means to develop anti-influenza drug leads. The lead compound 3-hydroxy-N-[(Z)-1-(5,6,7,8-tetrahydronaphthalen-2-yl) ethylideneamino]naphthalene-2-carboxamide, which we denoted as "HENC", was identified by its ability to increase the melting temperature of the effector domain (ED) of the NS1 protein, as assayed using differential scanning fluorimetry. A library of HENC analogs was tested for inhibitory effect against influenza A virus replication in MDCK cells. A systematic diversification of HENC revealed the identity of the R group attached to the imine carbon atom significantly influenced the antiviral activity. A phenyl or cyclohexyl at this position yielded the most potent antiviral activity. The phenyl containing compound had antiviral activity similar to that of the active form of oseltamivir (Tamiflu), and had no detectable effect on cell viability.

MODULATORS OF CFTR

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.

2-Hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-1-pyrazolyl] -1-benzenesulfonamide (DRF-4367): An orally active COX-2 inhibitor identified through pharmacophoric modulation

Analogs of 1,5-diarylpyrazoles with a novel pharmacophore at N1 were designed, synthesized and evaluated for the in-vitro cyclooxygenase (COX-1/COX-2) inhibitory activity. The variations at/around position-4 of the C-5 phenyl ring in conjunction with a CF3 and CHF2 groups at C-3 exhibited a high degree of potency and selectivity index (SI) for COX-2 inhibition. The in-vivo evaluation of these potent compounds with a few earlier ones indicated the 4-OMe-phenyl analog 6 and the 4-NHMe-phenyl analog 9 with a CF3, and the 4-OEt-phenyl analog 19 with a CHF2 group at C-3 to possess superior potency than celecoxib. In addition to its impressive anti-inflammatory, antipyretic, analgesic and anti-arthritic properties, compound 6 (DRF-4367) was found to possess an excellent pharmacokinetic profile, gastrointestinal (GI) safety in the long-term arthritis study and COX-2 potency in human whole blood assay. Thus, compound 6 was selected as an orally active anti-inflammatory candidate for pre-clinical evaluation.

Syntheses of compounds active toward glutamate receptors: I. New preparative synthesis of aminoindandicarboxylic acid (AIDA)

A preparative procedure has been developed for the synhtesis of 1-aminoindan-1,5-dicarboxylic acid which is a new group I metabotropic glutamate receptor antagonist.

The role of internal twisting in the photophysics of stilbazolium dyes

The synthesis of selectively bridged stilbazolium dyes related to DASPMI is described. The comparison of steady-state and time-resolved fluorescence studies as a function of temperature allows one to develop a kinetic model on the basis of which the high photostability and absence of photoisomerization for these dyes can be understood. There are two possible photochemical deactivation channels: non-radiative decay through single-bond twisting which does not lead to a distinguishable photoisomer and through double bond twisting leading to trans-cis photoisomerization. The latter process is more than one order of magnitude slower than single-bond twisting for these compounds and is only observed in the compound where both single bonds are bridged. Lifetime maxima observed at low temperature indicate a further early structural relaxation not connected with bond twisting but with bond length changes.

Highly regio- and stereoselective cocyclotrimerization and linear cotrimerization of α,β-unsaturated carbonyl compounds with alkynes catalyzed by nickel complexes

Cyclic enones 2-cyclohexen-1-one (1a), 4,4-dimethyl-2-cyclohexen-1-one (1b), 2-cyclopenten-1-one (1c), and 2-cyclohepten-1-one (1d) react with octa- 1,7-diyne (2) in THF in the presence of Ni(PPh3)2I2, ZnI2, and Zn powder at 62 °C to give [2 + 2 + 2] cycloaddition-dehydrogenation products 3a-d in 32-80% yields, α,β-Unsaturated lactone 5a (5,6-dihydro-2H-pyran-2-one) undergoes [2 + 2 + 2] cycloaddition with 2 to give both the corresponding cyclohexadiene product 6 (29%) and dehydrogenation product 7 (39%). Under similar reaction conditions, 3-buten-2-one reacts with 2 and various substituted hepta-1,6-diynes 9a-c to give [2 + 2 + 2] cycloaddition- dehydrogenation products 11a-d in 68-80% yields. Diphenylacetylene also reacts with 1a-d, 5a, and 2(5H)-furanone (5b) to afford the corresponding [2 + 2 + 2] cocyclotrimerization products 13a-d and 14a-b. No dehydrogenation of products 13 and 14 was observed under the reaction and workup conditions. The reactions of acrylates with alkynes catalyzed by nickel complexes give products that depend greatly on the reaction conditions. Treating ethyl acrylate (15a) with 1-phenyl-1-propyne (16) in the presence of Ni(PPh3)2Cl2 and Zn at 90 °C in toluene affords cocyclotrimerization product 19a as the major product (54% yield). However, treatment of CH2CHCOOR (R = Et and t-Bu) with mono alkynes 16 and 12 in the presence of Ni(PPh3)2X2 (X = Cl and I) and Zn powder in toluene at 60 °C affords the corresponding conjugated trienes 17a-c in 82-92% yields. The MS data of 17 firmly support an adduct of two molecules of alkyne and a molecule of acrylate. Similarly, the reaction of 15a with octa-1,7-diyne in the presence of Ni(PPh3)2I2, ZnI2, and zinc gives triene derivative 21 in 68% yield. NOE and X-ray results indicate that in these trienes the substituents from each alkyne and alkene moiety are cis to each other. The unique stereoselectivity can be attributed to the exclusive formation of seven- membered nickelacycloheptadiene intermediate 25 during the catalytic reaction.

Selective κ-opioid agonists: Synthesis and structure-activity relationships of piperidines incorporating an oxo-containing acyl group

This study describes the synthesis and the structure-activity relationships (SARs) of the (S)-(-)-enantiomers of a novel class of 2- (aminomethyl)piperidine derivatives, using κ-opioid binding affinity and antinociceptive potency as the indices of biological activity. Compounds incorporating the 1-tetralon-6-ylacetyl residue (30 and 34-45) demonstrated an in vivo antinociceptive activity greater than predicted on the basis of their κ-binding affinities. In particular, (2S)-2-[(dimethylamino)methyl]- 1-[(5,6,7,8-tetrahydro-5-oxo-2-naphthyl)acetyl]piperidine (34) was found to have a potency similar to spiradoline in animal models of antinociception after subcutaneous administration, with ED50s of 0.47 and 0.73 μmol/kg in the mouse and in the rat abdominal constriction tests, respectively. Further in vivo studies in mice and/or rats revealed that compound 34, compared to other selective κ-agonists, has a reduced propensity to cause a number of κ-related side effects, including locomotor impairment/sedation and diuresis, at antinociceptive doses. For example, it has an ED50 of 26.5 μmol/kg sc in the rat rotarod model, exhibiting a ratio of locomotor impairment/sedation vs analgesia of 36. Possible reasons for this differential activity and its clinical consequence are discussed.

188. Addition of Carbon Nucleophiles to Tricarbonylchromium Complexes of 1,2-Dihydrocyclobutabenzene, Indane, 1,2,3,4-Tetrahydronaphthalene and ortho-Xylene

3-Substituted 1,2-dihydrocyclobutabenzenes (bicycloocta-1,3,5-triene) are readily accessible from (1) via a two-step sequence which involves addition of a nucleophile and oxidation of the intermediate anionic